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Immunization  of mammals  with  purified  acetylcholine receptor  protein 
(AChR) 1 results in an autoimmune response to skeletal muscle AChR which 
impairs neuromuscular  transmission, causing experimental autoimmune myas- 
thenia gravis (EAMG).  In the introduction to the accompanying article (1) the 
striking similarities between EAMG and the human disease myasthenia gravis 
(MG) were reviewed. In that article we showed that immunization of rats with 
purified syngeneic AChR protein or AChR from fish electric organs induced an 
autoimmune response to muscle AChR. Antibodies to AChR were found both 
free in serum and bound to muscle AChR.  Also,  a  large decrease in AChR 
content was noted. In this paper we investigate the role of antibodies to AChR in 
the impairment of neuromuscular  transmission in EAMG by passively transfer- 
ring antibody from rats with EAMG to normal rats. 
Passive transfer experiments are intended to clarify the relative contribution 
of cell-mediated and humoral immunity to causing the changes in AChR func- 
tion, AChR content, and postsynaptic membrane structure which are responsi- 
ble for impairment of neuromuscular transmission. Previous experiments sug- 
gest that passive transfer of EAMG with antibody should be possible.  Antisera 
from animals with EAMG block AChR activity on muscle (2,  3) and electric 
organ cells (4-6) in vitro. Chronic administration to mice of large amounts of 
immunoglobulin from patients with MG resulted in decreased miniature end- 
plate potential amplitude and diminished toxin binding to end-plates (7). High 
titers of  antibody to AChR have been found in the serum of  babies suffering from 
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neonatal myasthenia (6). Although transplacental transfer of  this antibody from 
the mother to the baby may be responsible for the transient myasthenia  ob- 
served in the baby,  it is also possible that sensitized lymphoid cells from the 
mother invaded the baby.  EAMG can be passively transferred with sensitized 
lymphocytes (8, 9), but this remains inconclusive since antibody-producing cells 
might be transferred as well. 
In this paper we show that EAMG can be passively transferred between rats 
with antibody to AChR. The disturbances at the neuromuscular junction in rats 
receiving  antibody  are very  similar to those  observed in rats suffering from 
acute EAMG. Acute EAMG occurs 8-10 days after immunization of rats with 
AChR (10) and is characterized by massive invasion of the end-plate by phago- 
cytic cells (11, 12). The appearance of phagocytic cells at the end-plates of rats 
receiving antibody to AChR shows that the cell-mediated response at the end- 
plate  during  acute  EAMG  is  antibody  dependent.  Phagocytic  cells  are  not 
observed during the transient remission from acute EAMG,  nor are they ob- 
served during chronic EAMG  (9,  10) which usually  begins coincident with a 
large increase in humoral antibody to muscle AChR around day 28 (6). 
Studies of rats with passively transferred EAMG reveals the existence of two 
control  mechanisms  acting  in  animals  surviving  with  chronic  EAMG.  One 
mechanism terminates the phagocytic invasion of the end-plate despite contin- 
ued  presence  of antibody.  Another mechanism  appears  to  alter  turnover  of 
AChR to  insure  a  critical  number  of functional  AChR despite  the  massive 
excesses of antibody to AChR present. 
Materials and Methods 
Inoculation of  Donor Rats.  Female Lewis rats aged 10 wk were immunized with 15 ~g of AChR 
from Electrophorus electricus (eel) in complete Freund's adjuvant and with Bordetella pertussis 
vaccine as additional adjuvant as previously described (10).  Control rats received adjuvants only. 
Preparation of Antibodies.  Sera obtained 25 or more days after inoculation were stored at 
-20°C. Crude immunoglobulin fractions were prepared from pooled sera by precipitation with 40% 
(NH4)2804; IgG was prepared by chromatography on DEAE cellulose. Crude immunoglobulin was 
used in all experiments unless otherwise specified. Dilutions were made from a stock solution 3.4- 
fold concentrated with respect to serum. The stock contained 59.4 mg/mt of protein and antibody to 
eel AChR at a concentration of 2.42 x  10 -6 M, of which 1.86 x  10  -7 M also recognized AChR from 
rat muscle.  For control experiments immunoglobulin from rats immunized only with adjuvant 
was diluted from a  3.2-fold concentrated stock containing 47.9 mg]ml of protein. 
AntioAChR Antibody  Assay.  Antibodies to rat muscle AChR were assayed by a  previously 
described  indirect  coprecipitation  radioimmunoassay  employing  as  antigen junctional  muscle 
AChR solubilized from normal rats and complexed with ~sI-a-bungarotoxin (6). Antibody concen- 
trations were  expressed  in  moles of ~2~I-a-bungarotoxin-binding sites precipitated per liter of 
serum.  The total amount of antibody contained in the serum of individual rats was calculated 
assuming a serum vol of 5 ml. 
Complement Fixation Assay.  For sensitizing indicator sheep red blood cells (SRBC), a dilution 
of heated rabbit anti-SRBC antiserum was selected which would completely lyse, but not aggluti- 
nate,  SRBC  in the  presence of sufficient complement.  Fresh guinea pig serum,  absorbed with 
SRBC  to  remove  "natural antibody",  was used  as  a  source  of complement at  a  concentration 
causing less than 100% lysis of sensitized SRBC. Rat anti-eel AChR serum (obtained in the chronic 
phase of EAMG, with a titer of 1.2 ×  10  -5 M) and adjuvant control rat serum were heated at 56°C 
for 30 min before testing. Eel AChR in Triton X-100 (0.5%) was serially diluted 10-fold in phos- 
phate-buffered saline, and Triton X-100 (0.5%) was serially diluted to provide a  control for any 
hemolytic or anti-complementary activity. Sera, AChR solutions, and diluted guinea pig comple- LINDSTROM~  ENGEL,  SEYBOLD~ LENNON~  AND  LAMBERT  741 
ment were  mixed at ratios 1:1:2.  After incubation at 37°C  for 45 rain,  an aliquot of each was 
tested  for  residual  complement  activity  by  mixing  with  sensitized  SRBC.  The  end  points  of 
hemolysis were read visually after being left at 37°C for 30 rain, then overnight at 4°C. 
Injection of  Antibody.  Antibody was injected in a vol of 1 ml in normal saline into the jugular 
vein of female Lewis rats anesthetized with ether. 
Clinical Evaluations.  After injection of antibody, rats were examined every 12 h  for signs of 
weakness and fatigability which were scored on a scale ranging from +  from weak cry and grip to 
+ + +  for moribund (10).  Rats were weighed daily. 
Electromyographic  Evaluations.  The  amplitude  of the  compound  muscle  action  potential 
evoked by a  supramaximal nerve stimulus was measured in both forelimbs, as described previ- 
ously (13).  A  decrement in amplitude of the response during repetitive stimulation at 5/s was 
expressed as the ratio of the fifth to the first response. 
Microelectrode  Studies.  Intracellular microelectrodes were used to record miniature end-plate 
potentials and end-plate potentials evoked by nerve stimulus in muscle fibers of forelimb toe 
flexors and diaphragm as described previously (14).  In each muscle the mean amplitude of 25 
miniature end-plate potentials was determined in each of an average of 20 fibers. 
Histological Studies.  Formalin post-fixed cryostat sections of forelimb muscles were reacted 
for cholinesterase with a-napthyl acetate as substrate and lightly counterstained with hematoxy- 
lin, as previously described (11,  12). 
Quantitation of Total Muscle AChR.  AChR was extracted from rat carcasses with Triton X- 
100,  labeled  with  125I-a-bungarotoxin,  and  precipitated  by  sequential  addition  of excess  rat 
antibodies to muscle AChR and goat anti-rat immunoglobulin as described in the accompanying 
paper (1). 
Quantitation of Muscle AChR Complexed In Situ with Antibody.  Concentration of antibody- 
AChR complexes in muscle extracts labeled with 12"~I-a-bungarotoxin was determined by direct 
precipitation with goat anti-rat immunoglobulin as described in the accompanying paper (1). 
Results 
Clinical Observations.  Within  12  h  after receiving a  single  intravenous 
injection  of 10.7  x  10  -1~  mol  of anti-rat  muscle AChR  antibody,  six  of six 
recipient rats examined in detail showed clinical signs of weakness and fatiga- 
bility, and the hunched posture and cupped hands characteristic of EAMG (10). 
Clinical signs were maximal at 48-60  h  and began to diminish by 72 h,  but 
recovery was not complete until later than 7 days after injection of antibody 
(Fig. 1). Within 24 h of antibody transfer, characteristic signs of chronic respira- 
tory disease  (porphyrin staining of tears and nasal secretions) became overt, 
peaking at 48 h  and beginning to resolve at 72 h. Loss of weight, which did not 
occur  in  rats  receiving immunoglobulin  from  donors  immunized only  with 
adjuvants (Fig. 2), had already begun at 24 h and peaked at 72 h. The weight loss 
probably  reflected tissue  dehydration due  to  the  rats'  inability  to  raise  (or 
sustain  raised)  their heads  to  the water bottles,  but  some degree of calorie 
deficiency may have occurred if chewing and swallowing were also impaired. 
Weight was not completely regained until more than a week later. The severity 
of clinical signs increased with increasing doses of antibody (Fig. 5). IgG purified 
from the crude immunoglobulin fraction used  for these  studies was  equally 
efficient in its capacity to transfer EAMG (Table I). 
Electrophysiological Signs of  Passive Transfer.  Evidence of a defect of neu- 
romuscular remission in rats injected with antibody to AChR was obtained by 
electromyography (Fig. 3). As in acute EAMG (14), but not chronic EAMG, the 
amplitude of compound muscle action potential evoked in forearm muscles by a 
supramaximal nerve stimulus was reduced to as low as 5% of normal on the 2nd 742  PATHOLOGICAL  MECHANISMS  IN  EAMG.II 
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FIG.  1.  Time-course of clinical signs of EAMG after a single injection of antibody to AChR. 
Rats received a  dose of 10.7  x  10  -11 mol of antibody to rat AChR  i.v. at time zero and were 
tested for clinical signs of EAMG at 12-h intervals thereafter. 
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Weight  loss  in  rats  receiving  antibody  to  AChR.  Rats  in  both  groups  received 
immunoglobulin  i.v.  at  time  zero.  One  group  (EAMG  Ig)  received  10.7  ×  l0  -11  mol  of 
antibody to rat AChR.  The other group (adjuvant control Ig) received an equal number of 
milligrams  of protein  (27 mg) from serum of rats immunized only with adjuvants. 
day  (Fig.  3).  This suggested that transmission had failed completely at many 
nerve-muscle junctions,  leaving  many  muscle fibers functionally  denervated. 
Also,  as  in  acute  EAMG  (13),  a  decrement  of the  muscle  response  occurred 
during repetitive  nerve stimulation  (Fig.  3).  This indicated that transmission 
failed in an increasing proportion of muscle fibers aider the first response. The 
fii~h response fell to an average of 70% of the first response, which is as large a 
decrement  as  observed  in  acute  EAMG.  A  decrement  in  excess  of  10%  is 
considered significant  (13). The time-course of severity was approximately par- 
allel for clinical  signs (Fig.  1), muscle action potential amplitude,  and electro- 
myographic decrement. 
Transmission  was studied at individual  neuromuscular junctions using mi- 
croelectrodes in both the forelimb muscles, which had been studied by electro- LINDSTROM,  ENGEL,  SEYBOLD,  LENNON,  AND  LAMBERT  743 
TASz.E I 
Comparison of  Passive Transfer of  EAMG by Crude Immunoglobulin and Purified IgG* 
Crude immunoglobulin  Purified IgG 
Dose 
Clinical state day 2 
Amount of AChR 
Amount antibody-AChR 
Amount serum antibody 
7.0  ×  10  -H mol 
+ 
4.52  x  10  -H mol/rat 
0.802  x  10  -H mol/rat 
1.35  x  10  -~ mol/rat 
7.3  x  10  -I~ mol 
++ 
2.23  x  10  -~1 tool/rat 
0.478  ×  10  -1~ mol/rat 
1.57  x  10  -H mol/rat 
* Two rats were given each dose and then evaluated on day 2. 
~-120 I-  A 
~100 ....  / 
~,  •  "  /- 
80  "" 






















Fro.  3. 
m 
I  Io 
•  , 
,-  I-  .I  I  I  I  /  / 
I  2  3  4  5  6  7  8 
DAY 
Time-course of electromyographic  signs  after  a  single  injection  of antibody  to 
AChR. (A) shows  the  decrement  in  electromyogram  amplitude  of  the left  forelimb  of  rats at 
intervals  after  receiving  10.7 x 10  -11  mol of  antibody  to  rat  AChR  at  time  zero.  (B)  shows  the 
average amplitude of  the first  response of  the left  forelimb of  the same rats.  These are the 
same animals used in Fig. 6. 
myography,  and also in the diaphragm.  As in acute EAMG  (14), the forelimb 
muscles were more severely affected than diaphragm. The pattern of abnormali- 
ties in a rat 2 days after receiving anti-AChR antibody was like that seen in the 
acute phase of actively induced EAMG.  When the diaphragm was transillumi- 
nated,  the end-plate  zone had a  greyish  appearance  which occurred in acute 
EAMG and was related to invasion of this zone by phagocytic cells (11, 12) and 
focal degeneration of the muscle fibers. Miniature end-plate potentials (mepps) 
produced by spontaneous release of ACh quanta from the nerve ending were not 
observed  in  many  fibers,  especially  in  forearm  muscles.  Failure  to  observe 744  PATHOLOGICAL MECHANISMS  IN  EAMG.II 
mepps  suggested  that  nerve  contact  with  muscle  might  be  interrupted  by 
phagocytic cells,  as in the case of acute EAMG (11,  12).  Consistent with this 
interpretation  was the observation that in many fibers nerve stimulation pro- 
duced no end-plate potential or action potential,  although the fibers responded 
to direct stimulation.  The average number of quanta released from the nerve 
endings  by a  nerve  impulse  in  fibers with  end-plate  potentials  was  only 48 
(normal 159-203 [14]) in the forearm muscle of a rat 2 days after injection. Such 
low values were seen only in acute phase of EAMG (14) and are consistent with 
the  interpretation  that  only small  areas of presynaptic  membrane  remain  in 
contact with persisting  residues of the postsynaptic membrane which escaped 
destruction during cellular invasion. End-plate potentials were severely reduced 
in  amplitude  in  forelimb muscles,  and therefore  frequently did not trigger  a 
muscle fiber action potential. Although end-plate potentials in the diaphragm 48 
h after antibody transfer were sufficient to trigger action potentials, neuromus- 
cular transmission was blocked by only one-fifth the amount of curare normally 
required.  As in both acute and chronic EAMG, the amplitude of those mepps 
which could be recorded was reduced. Fig. 4 shows that the time-course for this 
effect was similar to that for clinical and electromyographic effects. 
Microscopic Studies.  Direct evidence of invasion  of the end-plate  zone by 
phagocytic  cells,  as  in  acute  EAMG,  was  obtained  by  microscopy  (Fig.  5). 
Postsynaptic membrane  regions were found split away from the muscle fiber, 
and macrophages were observed interposed between nerve ending and muscle 
fiber. As in acute EAMG (11,  12) some of the fibers showed segmental necrosis 
and invasion by macrophages. This began immediately adjacent to the end-plate 
and  extended  from  there  for  distances  of up  to  200  t~m  in  either  direction. 
Splitting  of the  postsynaptic  region  from  the  muscle  fiber  and  the  cellular 
reaction  were  first  observed at  24  h.  At this  time  only a  few fibers showed 
segmental necrosis. By 48 h more than half of the end-plates were splitting from 
the fibers or were invaded by macrophages, and about 10% of the fibers showed 
segmental  necrosis.  Between  48  h  and  5  days  the  cellular  reaction  almost 
completely disappeared, and the necrotic fiber segments were replaced by regen- 
erating fiber segments.  Detailed electron microscQpic studies of rats with pas- 
sively transferred  EAMG, including the localization of antibody and AChR on 
the postsynaptic membrane,  are in preparation  (Sakakibara,  Engel, and Lind- 
strom). 
Complement Fixation  by Anti-AChR Antibody.  Since complement fixation 
by antibodies bound to AChRs on the postsynaptic membrane might contribute 
to local damage of the membrane and/or be involved in mediating the cellular 
invasion which occurred, rat antisera to AChR were tested for their ability to 
bind complement aider interaction with solubilized AChR. Table II shows that 
rat antibodies to eel AChR can bind guinea pig complement after binding to eel 
AChR. This suggests that the cross-reacting antibodies bound to AChR on the 
postsynaptic membranes of rat muscle probably also bind complement. 
Biochemical Studies.  The amount ofanti-AChR antibody (10.7 x  10  -11 mol) 
injected into recipient rats was one-third the serum content of a rat in the donor 
pool. This amount of antibody was double that required to bind the total body 
content of AChR (5.30 x  10  -11 mol) in the recipients.  Changes in muscle AChR LINDSTROM,  ENGEL,  SEYBOLD,  LENNON,  AND  LAMBERT  745 
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FIG.  4.  MEPP amplitude in muscles of rats with passively transferred EAMG. Miniature 
end-plate potential amplitudes were measured in (A) forearm muscle and (B) diaphragm 
muscle of rats sacrificed at intervals after receiving 10.7  x  10 -]1 mol of antibody to rat 
muscle AChR (O) or 34.2 mg of adjuvant control immunoglobulin (t). Parallel lines delimit 
control values previously established (14). 
content in recipient rats were similar in time-course to those observed during 
the acute phase of EAMG starting  6 days after immunization  with AChR (1). 
With this amount of antibody, changes in AChR content were somewhat larger 
and  more  uniform  than  observed after  immunization.  AChR extracted  from 
muscle 6 h after injection of antibody was found to be complexed with antibody 
(Fig. 6). In addition, the absolute amount of AChR extracted was decreased. By 
24 h, the amount of total extractable AChR had decreased to less than half the 
normal  amount  (Fig.  6),  but  there  was  no  change  in  the  amount  of AChR 
complexed with  antibody.  Between days  3  and  4  the  total  amount  of AChR 
returned  to normal  levels.  At this time neuromuscular  transmission  was im- 
proving  (Figs.  1,  3,  and 4).  By day 5,  when neuromuscular  transmission  was 
demonstrable  in  almost  all  fibers,  the  content  of AChR  exceeded  normal 
amounts  (Fig.  6).  This  suggested  that  extrajunctional  AChR may have  been 
synthesized in fibers which were functionally denervated on days 1-3.  Repair 
synthesis no doubt contributed much to the total as well. Although the AChR 
content had commenced to decrease toward normal levels by day 6, perhaps in 
response to reinnervation  which appeared to be occurring on days 4 and 5, the 
absolute amount of AChR was still slightly elevated after 8 days. During days 1- 
3 about 30% of the AChR remaining in the muscle was complexed with antibody 746  PATHOLOGICAL  MECHANISMS  IN  EAMG.II LINDSTROM,  ENGEL,  SEYBOLD,  LENNON,  AND  LAMBERT 
TABLE  II 
Consumption of Guinea Pig Complement by the Interaction of Eel 
AChR and Rat Anti-AChR Serum 
747 
Moles AChR 
(x  10 -'3) 
Percent lysis of sensitized SRBC 
Adjuvant rat  Rat anti-AChR 
serum  serum 
568*  0  0 
56.85  >75  0 
5.68  >75  0 
0.568  >75  >75 
0.0568  >75  >75 
0  >75  >75 
* Hemolysis was completely inhibited in the presence of a  concentration of 
Triton X-100 equivalent to that contained in this concentration of AChR. 
$ This value represents approximate equivalence to the amount of anti-AChR 
antibody in the assay. 
(Fig.  6).  During days 4-8, when the clinical state of the animals  was greatly 
improving,  a  smaller fraction of the total AChR was complexed with antibody, 
but the total amount of complexes was increased. By 8 days neither the clinical 
state nor the  total AChR content had returned  entirely to normal,  and  some 
muscle AChR was still complexed with antibody. The serum content of antibody 
decreased  approximately  linearly  for  the  first  3  days  (Fig.  6).  Thereafter  it 
decreased more slowly. After day 5 more antibody was present complexed with 
AChR in muscle than was present in serum. 
To determine the efficiency of passive transfer, clinical and biochemical signs 
of EAMG were evaluated in rats injected with graded amounts of antibody to 
AChR (Fig. 7). The lowest dose of antibody tested (1  x  10-" mol) induced both 
clinical signs of EAMG, a decrease in the amount of muscle AChR, and complex- 
ing of muscle AChR with antibody. Theoretically this dose would be capable of 
binding only 17% of the total amount of AChR contained in the musculature of a 
normal rat,  and this amount of antibody represents only 4% of the anti-AChR 
content of a  rat in the donor pool. The decrease in amount of muscle AChR 2 
days  after  passive  transfer  was  almost  directly  proportional  to  the  dose  of 
antibody injected. The amount ofAChR complexed with antibody in the muscles 
Fro.  5.  Specimens from forelimb digit extensor muscle 6 h (A), 24 h  (B), 48 h (C, D, E) and 
5 days (F) after passive transfer. The cholinesterase-reactive parts of the end-plates appear 
as dark, homogeneous spots in these photographs and are easily distinguished during direct 
observation by their rod color as distinct from the blue of stained nuclei. No abnormality is 
seen at 6 h  (A). At 24 h  (B) there are necrotic fibers invaded by macrophages (arrowheads), 
and the end-plate (arrow) is separated from the underlying fiber by invading cells. At 48 h 
about  10%  of the  fibers are  invaded by macrophages  (C).  Fragments  of cholinesterase- 
reactive end-plate region (arrow) can still be observed while the underlying fiber region is 
invaded  by  macrophages  (D).  Mononuclear  cells  invading end-plate  (arrow)  at  higher 
magnification (E). At 5 days (F) the cellular reaction has subsided. Cholinesterase-reactive 
regions are of smaller size than at 6 h  (compare with A). A and B: x  480; C:  x  190; D:  x  480; 
E:  ×  770; F: 310. 748  PATHOLOGICAL MECHANISMS  IN  EAMG.II 
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Fro.  6.  Changes  in content of serum antibody, muscle AChR, and antibedy-AChR com- 
plexes  after injection of antibedy to AChR. At time zero rats were injected with 10.7 x 10-" 
mol of  antibody to AChR. Thereafter, all were tested electromyographically (Fig. 3), and at 
intervals  two rats were sacrificed for biochemical studies.  Values for content per rat of 
serum antibody (O), AChR (m), and antibody-AChR complexes (t) generally differed less 
than 10% between the two animals. 
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FIO. 7.  Dose-response curves for passive transfer of EAMG with increasing amounts of 
antibody to AChR. Each point is the average of two rats receiving the indicated dose of 
antibody 2 days before assay. 
of recipient rats at day 2 did not increase in direct proportion to the amount of 
antibody  injected,  but  plateaued  at  a  low  level.  Doses  of 17  x  10  -11  mol  of 
antibody were lethal to some rats in 2 days, yet this dose is less than the average 
content (27  x  10 -u mol) of serum antibody in the rats with chronic EAMG in the 
donor pool. 
To test  whether  passive  transfer  of EAMG would trigger a  self-sustaining 
autoimmune response  to AChR by presenting antibody-AChR complexes and 
immunogenic fragments of postsynaptic membrane to immunocompetent cells 
in  the  recipients,  a  group  of 10  recipient  rats  was  studied  for  72  days  after LINDSTROM,  ENGEL,  SEYBOLD,  LENNON,  AND  LAMBERT  749 
TABLE  III 
Absence of Immune Response to AChR at Prolonged Times After Passive Transfer 
Initial 
dose of 
Antibody at day 21  Antibody at day 72  AChR at day 72 
Group  antibody  x  10-" mol/rat  x  10 -H mol/rat  ×  10  -~1 mol/rat 
x  10 -H 
mol/rat 
Normal recipients (5)  7.0  0.35  -  0.17  0.00  -+ 0.19  6.23  -+ 0.06 
Adjuvant  immunized  7.0  0.32  ±  0.17  0.043  _  0.06  6.69 
recipients (5) 
passive transfer of antibody. The rats were given 7  x  10  -n mol of antibody to 
muscle AChR, and five received additionally 2  x  10  TM B. pertussis organisms 
subcutaneously to enhance their immune responsiveness. Although all 10 rats 
showed the expected signs of EAMG in the days immediately after injection of 
antibody, none showed signs of a second phase within the next 72 days, no anti- 
AChR antibody was detectable in the sera after 21  days, and muscle AChR 
content of recipient rats was normal at 72 days (Table III).  Therefore, passive 
transfer to EAMG did not trigger an autoimmune response. 
Discussion 
Passive transfer of anti-AChR antibody from rats with  chronic EAMG to 
normal rats caused signs of acute EAMG in the recipients. Features of MG and 
acute, chronic, and passively transferred EAMG referred to in this paper are 
compared in Table IV. The most striking similarity between passive and acute 
EAMG, and the basis of their difference from chronic EAMG and MG,  is the 
cellular invasion of the end-plate region. Phagocytic invasion of the end-plates 
in rats receiving antibody to AChR suggests that the cells observed at the end- 
plate during acute EAMG are not primarily lymphocytes sensitized to AChR, 
but rather nonspecific macrophages responding to antibody bound to AChRs in 
the postsynaptic membrane, and perhaps also responding to local complement- 
mediated membrane damage. Electron microscopic studies of both acute (11, 12) 
and passive EAMG (Sakakibara, Engel, and Lindstrom, manuscript in prepara- 
tion) clearly show that the cells observed in the end-plate are macrophages. The 
involvement of macrophages in passive transfer explains the efficiency of the 
process, since low doses of antibody sufficient to bind only part of the AChRs in 
the membrane could mark much of the postsynaptic membrane for destruction 
by the phagocytic cells. 
Antibody to AChR might alter neuromuscular transmission by at least five 
mechanisms: (a) antibody may partially or completely inhibit activity of the 
AChR molecule to which it is bound; (b) antibody may cause modulation of the 
AChR to which it is bound; (c) antibody-induced  modulation of AChR may cause 
increased synthesis of AChR; (d) antibody bound to AChR may fix complement 
and cause localized destruction of the postsynaptic membrane; and (e) antibody 
bound  to  AChR  may mark  the  postsynaptic membrane for destruction by 
macrophages.  Evidence that  the  first  mechanism occurs  in  EAMG  is  that 
antisera from animals with EAMG block AChR activity on muscle (2, 3) and 
electroplax (4-6) even after inhibition of complement. Decreased ACh sensitiv- 750  PATHOLOGICAL  MECHANISMS  IN  EAMG.II 
TABLE  IV 
Comparison  Between Features  of Passive, Acute, and Chronic EAMG and MG 
Passive  Acute  Chronic  MG 
EAMG  EAMG  EAMG 
Clinical 
1)  Weakness  +  +  ÷  + 
2) Fatigability  +  +  +  + 
Electrophysiological 
1) Decrementing electromyogram  +  +  +  + 
2) Repair of electromyogram with ACh esterase in-  +  +  +  + 
hibitor 
3)  Reduced mepp amplitude  +  +  +  + 
4) Increased curare sensitivity  +  +  +  + 
5) Decreased ACh sensitivity  NT  NT  +  + 
6)  Reduced muscle action potential amplitude  +  +  -  - 
7)  Fibers without end-plate potentials  +  +  -  - 
8)  Reduced resting potential  NT  +  -  - 
Histological 
1) Reduced toxin binding at end-plates  NT  NT  +  + 
2)  Reduced number of postsynaptic folds  -  -  +  + 
3)  Focal destruction of the postsynaptic membrane  +  +  +  - 
4) Phagocytic invasion of end-plate  +  +  -  - 
5)  Segmental necrosis of some fibers  +  +  -  + 
Biochemical 
1) Decreased AChR content 
2) Transient increased AChR content 
+  +  +  + 
+  +  -  _ 
Immunological 
1) 7S antibodies to muscle AChR  +  +  +  + 
2)  Complement fixation by anti-AChR antibodies  +  NT  +  + 
3) Antibodies not directed at AChR binding site  +  +  +  + 
4) Antibodies bind to muscle AChR in vivo  +  +  +  + 
5) Antibodies block AChR activity in vitro  +  NT  +  NT 
6) Average  concentration  of  antibodies  to  muscle  NT  -  +  + 
AChR >10  -8 M 
7)  Average  concentration  of  antibodies  to  muscle  NT  +  -  - 
AChR <10 .8 M 
8)  19S antibodies to muscle AChR  -  +  -  - 
9) Positive skin test response to AChR  NT  +  -  NT 
NT, not tested. 
ity (3), increased  curare  sensitivity  (14), and small mepps  (14) could be explained 
by  either  antibody  blockage  of AChR  activity  or  reduced  amounts  of AChR. 
Evidence  suggestive  of antibody-induced  modulation  of AChR  is the persistence 
of decreased  amounts  of AChR  in  chronic  EAMG  (1).  Increased  synthesis  of 
AChR  in chronic EAMG  is suggested  by the observation  of substantial  amounts 
of AChR  unlabeled  by  antibody  (1).  This  is  striking  because  passive  transfer 
experiments  show that  the  large  excesses of antibody  in the  serum  of rats  with 
chronic  EAMG  have  ready  access  to  the  end-plate;  so,  if AChR  there  were 
turning  over at the normal  low rate  (15,  16), then  all the AChR  should rapidly be LINDSTROM,  ENGEL,  SEYBOLD,  LENNON,  AND  LAMBERT  751 
labeled with antibody. In this paper we presented evidence that antibody to 
AChR in rats with EAMG can fix complement on interaction with soluble eel 
AChR. Serum from MG patients can also fix complement on binding to particu- 
late eel AChR (17). Thus, it is likely that binding of antibody to AChR in the 
postsynaptic membrane might also  cause  fixation of complement and  focal 
membrane destruction. Focal postsynaptic membrane destruction is observed in 
both acute and chronic EAMG (11, 12). Phagocytic invasion of the end-plates 
during passive EAMG is striking evidence that antibody to AChR can target the 
postsynaptic membrane for destruction. 
The relative importance of the various mechanisms by which antibody might 
inhibit neuromuscular  transmission varies during the course of EAMG. Clinical 
and  electrophysiological signs  approximately parallel  AChR amount in  the 
course of passive transfer. The decrease in AChR, in turn, as in acute EAMG, 
must in large part be related to phagocytic activity at the end-plate which also 
directly topologically impairs transmission. Before phagocytosis, and at end- 
plates that are not phagocytized, antibody-induced modulation of AChR and 
blockage of AChR activity may be important factors in impairing neurotrans- 
mission.  In chronic EAMG,  decreased AChR content per se is probably the 
principal factor in impairing transmission, and antibody bound to many of the 
remaining AChRs probably also contributes to impaired transmission (1). 
The role of antibodies to AChR in impairing neuromuscular transmission in 
human MG does not appear to include marking the postsynaptic membrane for 
destruction by macrophages (18), though small amounts of phagocytic activity 
might go undetected. As in the case of chronic EAMG, high concentrations of 
serum immunoglobulin G recognizing muscle AChR are present (6), and these 
can be used to passively transfer MG to mice (7). In that case, transfer required 
high doses administered chronically over many days, perhaps because of the 
limited cross-reaction between human and mouse AChRs,  and also perhaps 
because of limited interaction between human antibody and mouse complement 
and macrophages. Phagocytic invasion of end-plates was not examined in that 
experiment. Because the factor terminating phagocytic invasion aider acute 
EAMG is unknown, it is even more difficult to speculate on the regulation of 
antibody-mediated cellular reactions in MG.  Passive transfer of MG between 
humans  appears  to  occur in  the  case  of neonatal  MG.  Antibody to  AChR 
apparently transferred across the placenta has been found in the serum of  babies 
suffering from this transient form of MG (6). 
We demonstrated that, aider the specific degeneration of postsynaptic mem- 
brane which occurs in passively transferred EAMG, an auteimmune response is 
not triggered, despite the presence of antibody-AChR complexes, phagocytic 
cells, and even a potent adjuvant (Table III). This means that, at least in the 
case of rats, simply presenting AChR to the immune system, even as multimeric 
aggregates in membrane with antibody attached, and even with systemic adju- 
vants, is not sufficient to trigger an autoimmune  response. The observation that 
EAMG intensity increases with the dose of AChR (10) is also consistent with this 
observation, since, if muscle AChR were immunogenic, then any dose of AChR 
sufficient to initiate breakdown of the postsynaptic membrane should instead 
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breakdown products of the initial attack. Since EAMG is induced by purified rat 
AChR  in  amounts  smaller  than  the  amounts  of AChR  affected  by passive 
transfer (1), the critical event allowing induction of EAMG by purified AChR is 
probably extraction of AChR from the membrane or denaturation  of the AChR 
during purification or emulsification in complete Freund's adjuvant. Similarly, 
the inductive event in human MG may involve alteration of the structure of the 
AChR found in muscle or in thymus (6). It is known that antibodies to AChR do 
not develop subsequent to degeneration of human muscle as occurs in muscular 
dystrophy or polymyositis (6). 
Summary 
Passive transfer  of experimental  autoimmune  myasthenia  gravis  (EAMG) 
was achieved using the gamma globulin fraction and purified IgG from sera of 
rats immunized withElectrophus electricus (eel) acetylcholine receptor (AChR). 
This demonstrates the critical role of anti-AChR antibodies in impairing neuro- 
muscular  transmission  in  EAMG.  Passive  transfer  of anti-AChR  antibodies 
from rats  with chronic  EAMG induced  signs of the acute phase of EAMG in 
normal  recipient  rats,  including  invasion  of the  motor  end-plate  region  by 
mononuclear  inflammatory  cells.  Clinical,  electrophysiological,  histological, 
and biochemical  signs of acute EAMG were observed by 24 h  aider antibody 
transfer.  Recipient rats developed profound weakness and fatigability, and the 
posture characteristic of EAMG. Striking weight loss was attributable to dehy- 
dration. Recipient rats showed large decreases in amplitude of muscle responses 
to motor nerve stimulation, and repetitive nerve stimulation induced character- 
istic decrementing responses. End-plate potentials were not detectable in many 
muscle fibers,  and  the  amplitudes  of miniature  end-plate  potentials  were re- 
duced in  the others.  Passively transferred  EAMG more severely affected the 
forearm muscles than diaphragm muscles, though neuromuscular transmission 
was impaired and curare sensitivity was increased in both muscles. Some AChR 
extracted from the muscles of rats with passively transferred EAMG was found 
to  be  complexed  with  antibody,  and  the  total  yield  of AChR  per  rat  was 
decreased. The quantitative decrease in AChR approximately paralleled in time 
the  course  of clinical  and  electrophysiological  signs.  The  amount  of AChR 
increased to normal levels and beyond at the time neuromuscular transmission 
was  improving.  The  excess of AChR  extractable  from  muscle  as  the  serum 
antibody level decreased probably represented extrajunctional receptors formed 
in response to functional denervation caused by phagocytosis of the postsynaptic 
membrane  by  macrophages.  The  amount  of antibody  required  to  passively 
transfer EAMG was less than  required to bind all AChR molecules in a  rat's 
musculature.  The  effectiveness  of small  amounts  of antibody  was  probably 
amplified by the activation of complement and by the destruction of large areas 
of postsynaptic membrane  by phagocytic cells.  A  self-sustaining  autoimmune 
response  to  AChR  was  not  provoked  in  animals  with  passively transferred 
EAMG. 
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